WallStSmart
LEGN

Legend Biotech Corp

NASDAQ: LEGN · HEALTHCARE · BIOTECHNOLOGY

$25.58
-4.62% today

Updated 2026-06-05

Market cap
$6.66B
P/E ratio
P/S ratio
5.85x
EPS (TTM)
$-1.38
Dividend yield
52W range
$16 – $45
Volume
2.6M

Legend Biotech Corp (LEGN) Financial statements

SEC filings — annual and quarterly data.

Profit margin
-28.85%
Operating margin
-13.27%
ROE
-25.85%
ROA
-5.24%
Debt/equity
0.40x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2017$23.59M$9.37M100.41%58.41%39.69%
2018$49.13M$-2.78M100.00%-3.12%-5.67%
2019$61.80M$-101.59M100.00%-214.42%-164.39%
2020$75.00M$-266.37M100.00%-417.79%-355.16%
2021$68.83M$-403.58M100.00%-569.97%-586.38%
2022$117.00M$-446.35M44.14%-389.40%-381.48%
2023$285.14M$-518.25M49.42%-154.13%-181.75%
2024$627.24M$-177.03M62.60%-48.35%-28.22%
2025$1.03B$-296.80M60.34%-13.27%-28.85%

Frequently asked questions

What is Legend Biotech Corp's revenue?

Legend Biotech Corp's trailing twelve-month revenue is $1.14B. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is LEGN?

In its most recent fiscal year, LEGN ran a gross margin of 60.34%, an operating margin of -13.27%, and a net margin of -28.85%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does LEGN generate?

LEGN produced $-168.04M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is LEGN's balance sheet healthy?

LEGN holds $901.90M in cash and equivalents against — in long-term debt, on $1.00B of shareholder equity. That debt is best read against the cash flow the business throws off each year.